Potential role of vascular targeted therapy to combat against tumor

Expert Opinion on Drug Delivery

Volumn 6, Issue 7, 2009, Pages 719-726

  Chen, Bei ^a   Jin, Haifeng ^a   Wu, Kaichun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis inhibitor; Combination therapy; Phage displayed peptide; Vascular disturbing agent; Vascular targeted therapy

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; COMBRETASTATIN A4; DENIBULIN; DOCETAXEL; ENDOSTATIN; INTERFERON; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; OXALIPLATIN; PEMETREXED; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SOBLIDOTIN; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ATAXIA; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONSTIPATION; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG ERUPTION; DRUG SAFETY; ENDOTHELIUM CELL; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; GLIOBLASTOMA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTESTINE ISCHEMIA; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; OVARY CANCER; PROSTATE CANCER; PROTEINURIA; RECURRENT CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; THYROID CANCER; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 67650348161     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903018871     Document Type: Review

References (84)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-1186 •• The initial hypothesis that angiogenesis is necessary for tumor growth and invasion.
2. Brem S. The role of vascular proliferation in the growth of brain tumors. Clin Neurosurg 1976;23:440-453
3. Brem S, Brem H, Folkman J, et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36(8):2807-2812
4. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-427 (Pubitemid 38173977)
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-410
6. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 2004;25(10):536-542 A review of synergistic therapeutic effects achieved through combining vascular targeted therapy with conventional antitumor therapies. (Pubitemid 39233566)
7. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11(2 Pt 1):416-420 •• A review of two distinct groups of vascular targeted therapies: antiangiogenic agents and vascular disrupting approaches, and their possible role in anticancer treatment.
8. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60(7):1878-1886 (Pubitemid 30207647)
9. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105(8):R15-24 (Pubitemid 30217701)
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342 (Pubitemid 38702844)
11. Kabbinavar FF, Schulz J, Mccleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697-3705 A randomized, Phase II trial comparing bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in CRC patients considered non-optimal candidates for first-line irinotecan. (Pubitemid 46252464)
12. Ciardiello F, Troiani T, Bianco R, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006;17 (Suppl 7):vii109-14 (Pubitemid 43985191)
13. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-364 (Pubitemid 26272076)
14. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-257
15. Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60(5):1388-1393 (Pubitemid 30152012)
16. Baluk P, Hashizume H, Mcdonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15(1):102-111 (Pubitemid 40127638)
17. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007;96(8):1159-1165 •• A review of vascular disrupting agents, including their mechanism of action and the results obtained in preclinical studies as well as in clinical trials.
18. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2(10):727-739
19. Sweeney CJ, Miller KD, Sledge GW. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003;9(1):24-29
20. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-989 (Pubitemid 32937367)
21. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312(5777):1171-1175
22. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003;9(6):1957-1971 (Pubitemid 36687614)
23. Sonveaux P, Brouet A, Havaux X, et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 2003;63(5):1012-1019 (Pubitemid 36278432)
24. Greenblatt M, Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 1968;41(1):111-124
25. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246(4935):1306-1309 (Pubitemid 20066716)
26. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989;8(12):3801-3806 (Pubitemid 20016061)
27. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998;34(13):2041-2045 (Pubitemid 28546939)
28. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001;84(10):1354-1362 (Pubitemid 32522104)
29. Okada F, Rak JW, Croix BS, et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998;95(7):3609-3614 (Pubitemid 28173175)
30. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70(10):779-787
31. Chen CT, Lin J, Li Q, et al. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther 2000;11(14):1983-1996 (Pubitemid 30743985)
32. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90(3):561-565 (Pubitemid 38297190)
33. Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, et al. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol 2000;164(1):217-222 (Pubitemid 30012993)
34. Kohn EC, Reed E, Sarosy G, et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996;56(3):569-573 (Pubitemid 26043655)
35. Hussain MM, Kotz H, Minasian L, et al. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol 2003;21(23):4356-4363 (Pubitemid 46621812)
36. Dutcher JP, Leon L, Manola J, et al. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study. Cancer 2005;104(11):2392-2399
37. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006;16(3):80-8 •• A review of ligand-directed vascular targeting strategies with an emphasis on recent developments related to phage-display-based screening.
38. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61(18):6811-6815 (Pubitemid 32896505)
39. Hadfield JA, Ducki S, Hirst N, Mcgown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003;5:309-325
40. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009;18(2):189-197
41. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 2004;13(9):1171-1182 (Pubitemid 39242740)
42. Schoffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004;15(4):671-679 (Pubitemid 38559607)
43. Tamura K, Nakagawa K, Kurata T, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother Pharmacol 2007;60(2):285-293 (Pubitemid 46742544)
44. Tolcher AW, Forero L, Celio P, et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. J Clin Oncol 2003;22(S) [AACR meeting abstract]
45. Sessa C, Lorusso P, Tolcher AW, et al. A pharmacokinetic and DCE-MRI-dynamic Phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. Proc Amer Assoc Cancer Res 2005;46 [ASCO meeting abstract]
46. Lorusso PM, Gadgeel SM, Wozniak A, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26(2):159-167
47. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 2009;22(1):115-128
48. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24(10):1491-1498 (Pubitemid 46638769)
49. Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006;12(9):2834-2840 (Pubitemid 43752124)
50. Ching LM, Cao Z, Kieda C, et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 2002;86(12):1937-1942 (Pubitemid 34888632)
51. Gabra H. Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. J Clin Oncol 2006;24(18S):263s
52. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99(12):2006-2012
53. Tandle A, Hanna E, Lorang D, et al. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 2009;115(1):128-139
54. Zarovni N, Monaco L, Corti A. Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides. Hum Gene Ther 2004;15(4):373-382 (Pubitemid 38469779)
55. Widakowich C, de Castro G Jr, de Azambuja E, et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12(12):1443-1455
56. Zurita AJ, Arap W, Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. J Control Release 2003;91(1-2):183-186 (Pubitemid 37288889)
57. Balestrieri ML, Napoli C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer 2007;43(8):1242-50 A review of the very recent advances in the identification of peptide ligands and their corresponding tissue-specific endothelial receptors through the phage display technology, with emphasis on ligand-directed delivery of therapeutic agents and targeted gene therapy. (Pubitemid 46729702)
58. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000;1(1):48-56
59. St CROIX B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289(5482):1197-1202 (Pubitemid 30650733)
60. Carson-Walter EB, Watkins DN, Nanda A, et al. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001;61(18):6649-6655 (Pubitemid 32896479)
61. Seaman S, Stevens J, Yang MY, et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007;11(6):539-554 Identifying genes that distinguish physiological and pathological angiogenesis using SAGE. (Pubitemid 46856908)
62. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990;249(4967):386-390 (Pubitemid 20248864)
63. Zhi M, Wu KC, Dong L, et al. Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer. Cancer Biol Ther 2004;3(12):1232-1235 (Pubitemid 41350958)
64. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000;10(6):435-442 (Pubitemid 32181913)
65. Xu L, Jin BQ, Fan DM. Selection and identification of mimic epitopes for gastric cancer-associated antigen MG7 Ag. Mol Cancer Ther 2003;2(3):301-306
66. Liang S, Lin T, Ding J, et al. Screening and identification of vascular-endothelial-cellspecific binding peptide in gastric cancer. J Mol Med 2006;84(9):764-773 (Pubitemid 44334966)
67. Giordano RJ, Cardo-Vila M, Lahdenranta J, et al. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001;7(11):1249-1253 (Pubitemid 33063782)
68. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002;8(7):751-755 (Pubitemid 34778730)
69. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002;8(2):121-127 (Pubitemid 34155122)
70. Enback J, Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans 2007;35(Pt 4):780-783 (Pubitemid 47310367)
71. Liu Z, Wu K. Peptides homing to tumor vasculature: imaging and therapeutics for cancer. Recent Pat Anticancer Drug Discov 2008;3(3):202-208
72. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49(6):879-886 (Pubitemid 351793427)
73. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrintargeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008;17(8):1225-1235
74. Hart SL, Knight AM, Harbottle RP, et al. Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J Biol Chem 1994;269(17):12468-12474 (Pubitemid 24202027)
75. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279(5349):377-380 (Pubitemid 28063372)
76. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60(3):722-727 (Pubitemid 30094573)
77. Garde SV, Forte AJ, Ge M, et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007;18(10):1189-1200 (Pubitemid 47480744)
78. Bieker R, Kessler T, Schwoppe C, et al. Infarction of tumor vessels by NGR-peptide directed targeting of tissue factor. Experimental results and first-in-man experience. Blood 2009;113(20):5019-5027
79. Porkka K, Laakkonen P, Hoffman JA, et al. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 2002;99(11):7444-7449 (Pubitemid 34568710)
80. Hui X, Han Y, Liang S, et al. Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. J Control Release 2008;131(2):86-93
81. Han Y, Hong L, Wu KC, et al. Identification of the receptor of CGNSNPKSC and its expression in gastric cancer. J Mod Oncol 2007;15(4):3
82. Davies JM, Goldberg RM. First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 2008;22(13):1470-1479
83. Giusti RM, Cohen MH, Keegan P, Pazdur R. FDA Review of a Panitumumab (VectibixTM) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer. Oncologist 2009;14(3):284-290
84. Alencar H, Funovics MA, Figueiredo J, et al. Colonic adenocarcinomas: near-infrared microcatheter imaging of smart probes for early detection-study in mice. Radiology 2007;244(1):232-238 (Pubitemid 46981978)